Salarius Pharmaceuticals (SLRX) Competitors $1.55 +0.14 (+9.93%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SLRX vs. OBSV, CDT, CERO, SNGX, COEP, NLSP, EYEN, EVOK, ADIL, and GRIShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include ObsEva (OBSV), Conduit Pharmaceuticals (CDT), CERo Therapeutics (CERO), Soligenix (SNGX), Coeptis Therapeutics (COEP), NLS Pharmaceutics (NLSP), Eyenovia (EYEN), Evoke Pharma (EVOK), Adial Pharmaceuticals (ADIL), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. ObsEva Conduit Pharmaceuticals CERo Therapeutics Soligenix Coeptis Therapeutics NLS Pharmaceutics Eyenovia Evoke Pharma Adial Pharmaceuticals GRI Bio Salarius Pharmaceuticals (NASDAQ:SLRX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Does the MarketBeat Community believe in SLRX or OBSV? ObsEva received 293 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. However, 54.17% of users gave Salarius Pharmaceuticals an outperform vote while only 51.12% of users gave ObsEva an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% ObsEvaOutperform Votes31951.12% Underperform Votes30548.88% Is SLRX or OBSV more profitable? Salarius Pharmaceuticals' return on equity of -140.28% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% ObsEva N/A -416.36%-92.01% Which has more volatility & risk, SLRX or OBSV? Salarius Pharmaceuticals has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Does the media favor SLRX or OBSV? In the previous week, ObsEva had 1 more articles in the media than Salarius Pharmaceuticals. MarketBeat recorded 1 mentions for ObsEva and 0 mentions for Salarius Pharmaceuticals. Salarius Pharmaceuticals' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score. Company Overall Sentiment Salarius Pharmaceuticals Neutral ObsEva Neutral Do insiders & institutionals have more ownership in SLRX or OBSV? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 1.4% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, SLRX or OBSV? Salarius Pharmaceuticals has higher earnings, but lower revenue than ObsEva. Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius Pharmaceuticals$1.84M1.21-$12.54M-$8.17-0.19ObsEva$20.11M0.00-$58.38M-$0.92N/A SummaryObsEva beats Salarius Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.03M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.1910.5990.0517.18Price / Sales1.21195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book0.145.094.784.78Net Income-$12.54M$151.83M$120.31M$225.60M7 Day Performance5.45%-2.13%-1.92%-1.23%1 Month Performance7.64%-3.10%11.51%3.36%1 Year Performance-66.95%11.54%30.61%16.60% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius PharmaceuticalsN/A$1.55+9.9%N/A-68.8%$2.03M$1.84M-0.1920Positive NewsOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCDTConduit PharmaceuticalsN/A$0.08-5.5%N/A-98.5%$7.92MN/A0.003CEROCERo TherapeuticsN/A$0.05-8.8%N/AN/A$7.77MN/A0.008SNGXSoligenix0.7327 of 5 stars$3.09-2.2%N/A-67.4%$7.76M$840,000.00-0.4220Positive NewsGap UpCOEPCoeptis Therapeutics0.3761 of 5 stars$0.19+5.5%N/A-83.7%$7.72M$80,000.00-0.612Gap UpNLSPNLS Pharmaceutics0.3636 of 5 stars$1.94+1.6%N/A+332.6%$7.40MN/A0.006News CoverageGap UpEYENEyenovia1.4874 of 5 stars$0.08-0.6%$2.00+2,309.6%-94.9%$7.18M$31,832.00-0.1140Gap DownHigh Trading VolumeEVOKEvoke Pharma0.0362 of 5 stars$4.71flatN/A-61.9%$7.02M$5.18M-0.434News CoverageADILAdial Pharmaceuticals3.3523 of 5 stars$1.09-0.1%$8.00+634.6%-38.9%$6.98MN/A0.0020News CoveragePositive NewsGRIGRI Bio2.5218 of 5 stars0.78-2.5%N/A-98.0%$6.97MN/A0.001 Related Companies and Tools Related Companies OBSV Competitors CDT Competitors CERO Competitors SNGX Competitors COEP Competitors NLSP Competitors EYEN Competitors EVOK Competitors ADIL Competitors GRI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRX Stock Alerts